GlassScriptPhysician profile
Jeffrey Mitchell Rhodes
NPI 1568490753
$2,360.88
in general payments reported to CMS, 2019-2025
12 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,589 · 2020: $94.33 · 2021: $43.18 · 2022: $24.69 · 2023: $157 · 2024: $223 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $1,312.22 | 2019-2021 | |
| Medtronic Vascular, INC. | $394.05 | 2019-2020 | |
| Medtronic, INC. | $192.21 | 2022-2025 | Concertotm |
| W. L. Gore & Associates, INC. | $162.98 | 2024 | Gore Tag Conformable Thoracic Endoprosthesis |
| Abbott Laboratories | $104.94 | 2023 | Jeti Peripheral Catheter |
| Impulse Dynamics (USA) INC. | $52.38 | 2023 | Optimizer |
| Boston Scientific Corporation | $31.18 | 2025 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Innovation Technologies INC | $24.89 | 2024 | Irrisept |
| Novartis Pharmaceuticals Corporation | $23.51 | 2024 | |
| Merck Sharp & Dohme LLC | $22.23 | 2025 | Verquvo |
| Baxter Healthcare | $20.60 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.69 | 2022-2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rhodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.